Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2010-N-0109]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA) has determined that the 15 drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements.
 FOR FURTHER INFORMATION CONTACT: Olivia Pritzlaff, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6308, Silver Spring, MD 20993-0002, 301-796-3601.


SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417) (the 1984 amendments), which authorized the approval of duplicate versions of drug products approved under an ANDA procedure. ANDA sponsors must, with certain exceptions, show that the drug for which they are seeking approval contains the same active ingredient in the same strength and dosage form as the “listed drug,” which is a version of the drug that was previously approved. Sponsors of ANDAs do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA). The only clinical data required in an ANDA are data to show that the drug that is the subject of the ANDA is bioequivalent to the listed drug. The 1984 amendments include what is now section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(j)(7)), which requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the “Approved Drug Products With Therapeutic Equivalence Evaluations,” which is generally known as the “Orange Book.” Under FDA regulations, a drug is withdrawn from the list if the agency withdraws or suspends approval of the drug's NDA or ANDA for reasons of safety or effectiveness, or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162).
                    ( print page 11550) Under § 314.161(a) (21 CFR 314.161(a)), the agency must determine whether a listed drug was withdrawn from sale for reasons of safety or effectiveness: (1) Before an ANDA that refers to that listed drug may be approved; (2) whenever a listed drug is voluntarily withdrawn from sale and ANDAs that refer to the listed drug have been approved; and (3) when a person petitions for such a determination under 21 CFR 10.25(a) and 10.30. Section 314.161(d) provides that if FDA determines that a listed drug was withdrawn from sale for reasons of safety or effectiveness, the agency will initiate proceedings that could result in the withdrawal of approval of the ANDAs that refer to the listed drug. FDA has become aware that the drug products listed in the table in this document are no longer being marketed. (As requested by the applicant, FDA withdrew approval of NDA 12-097 for KENALOG IN ORABASE (triamcinolone acetonide) Dental Paste in the 
                    **Federal Register**
                     of February 11, 2009 (74 FR 6896).) Application No.
Drug
ApplicantNDA 8-732
PRO-BANTHINE (propantheline bromide) Tablets, 7.5 milligrams (mg) and 15 mg
Shire Pharmaceuticals, Inc.,725 Chesterbrook Blvd., Wayne, PA 19087)NDA 12-097
KENALOG IN ORABASE (triamcinolone acetonide) Dental Paste, 0.1%
Apothecon, Inc., c/o Bristol-Myers Squibb, P.O. Box 4500, Princeton, NJ 08543-4500NDA 12-141
CYTOXAN (cyclophosphamide) Tablets, 25 mg and 50 mg
Baxter Healthcare Corp., 1620 Waukegan Rd. MPGR-AL, McGaw Park, IL 60085NDA 17-498
MICRONASE (glyburide) Tablets, 1.25 mg, 2.5 mg, and 5 mg
Pharmacia and Upjohn Co., 7171 Portage Rd., Kalamazoo, MI 49001NDA 17-924
TAGAMET (cimetidine HCl) Oral Solution, Equivalent to (EQ) 300 mg base/5 mL
GlaxoSmithKline, 5 Moore Dr., P.O. Box 13398, Research Triangle Park, NC 27709-3398NDA 18-207
DESYREL (trazodone HCl) Tablets, 50 mg, 100 mg, 150 mg, and 300 mg
Apothecon, Inc.NDA 19-425
TRANDATE (labetalol HCl) Injection, 5 mg/mL
Prometheus Laboratories, Inc., 9410 Carroll Park Dr., San Diego, CA 92121NDA 20-101
PROZAC (fluoxetine HCl) Oral Solution, EQ 20 mg base/5 mL
Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285NDA 20-286
MONOPRIL-HCT (fosinopril sodium; hydrochlorothiazide) Tablets, 10 mg/12.5 mg, 20 mg/12.5 mg
Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, NJ 08543-4000NDA 20-664
DOSTINEX (cabergoline) Tablet, 0.5 mg
Pharmacia and Upjohn Co.NDA 20-683
ALESSE (ethinyl estradiol; levonorgestrel) Tablets (21 Tablets and 28 Tablets), 0.02 mg; 0.1 mg
Wyeth Pharmaceuticals Inc., P.O. Box 8299, Philadelphia, PA 19101-8299NDA 20-801
PEPCID AC (famotidine) Chewable Tablet, 10 mg
Merck Research Laboratories, Sumneytown Pike BLA 20, P.O. Box 4, West Point, PA 19486-0004NDA 20-860
LEVLITE (ethinyl estradiol; levonorgestrel) Tablets (21 Tablets and 28 Tablets), 0.02 mg; 0.1 mg
Bayer Healthcare Pharmaceuticals, Inc., 340 Changebridge Rd., P.O. Box 1000, Montville, NJ 07045-1000NDA 21-455
BONIVA (ibandronate sodium) Tablet, EQ 2.5 mg base
Hoffmann LaRoche, Inc., 340 Kingsland St., Bldg. 719/4, Nutley, NJ 07110-1199NDA 50-517
MEFOXIN (cefoxitin sodium) Injection, EQ 1 gram (g) base/vial and EQ 2 g base/vial
Merck and Co., Inc., Sumneytown Pike BLA 20, P.O. Box 4, West Point, PA 19486-0004
 FDA has reviewed its records and, under § 314.161, has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. Accordingly, the agency will continue to list the drug products listed in this document in the “Discontinued Drug Product List” section of the Orange Book. The “Discontinued Drug Product List” identifies, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness. Approved ANDAs that refer to the NDAs listed in this document are unaffected by the discontinued marketing of the products subject to those NDAs. Additional ANDAs that refer to these products may also be approved by the agency if they comply with relevant legal and regulatory requirements. If FDA determines that labeling for these drug products should be revised to meet current standards, the agency will advise ANDA applicants to submit such labeling. Dated: March 8, 2010. Leslie Kux, Acting Assistant Commissioner for Policy.


[FR Doc. 2010-5275 Filed 3-10-10; 8:45 am] BILLING CODE 4160-01-S